Latest News


Xceleron latest presentation

June 11, 2015

Surveying the Boundaries of Accelerator Mass Spectrometry: The Widening Scope of an Evolving Technology

Read the presentation

 

New Xceleron presentation 9th June

June 1, 2015

Dr. Stephen English Surveying the boundaries of accelerator mass spectrometry: the widening scope of an evolving technology
12th International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, Princeton NJ
June 9th
16:20 – 16:40
Session 6
McDonnell AO1

 

New webinar materials are now available to view

April 22, 2015

Go here to download speaker presentations, listen to and watch a recording of the presentations or read our comprehensive Q&A

 

How AMS detection works

April 1, 2015

Our concise two-pager was written by our AMS engineer Eric Guarin

Download How AMS Detection Works

 

Xceleron Webinar 26 March 2015

March 18, 2015

Successful clinical 14C microtracer investigations: What can contemporary AMS do for you?

Register here

 

Xceleron Retains Professor Graham Lappin as Subject-Matter Expert

January 26, 2015

Expertise enables new AMS applications, Xceleron grows analytical operations

(Germantown, MD, USA; January 26, 2015) –Xceleron, a leader in the use of microtracers and Accelerator Mass Spectrometry (AMS) in novel life sciences investigations, has announced that it is retaining the consulting services of Graham Lappin (Visiting Professor of Pharmacology at the University of Lincoln, UK). Professor Lappin will advise the company and its customers on the application of microtracers in drug target research, clinical development and new non-pharmaceutical applications.

Professor Lappin has a long history and deep connections with the company going back to its early days. He also played an important role during Xceleron’s growth from a research-oriented laboratory in the UK to present-day in the US where it develops robust fit-for-purpose analytical methodology associated with AMS.

“Our relationship with Graham is important at this time for Xceleron” said Dr Michael Butler, CEO of Xceleron. “We have established a reputation for delivering representative, accurate and precise analytical data using AMS detection. This has been achieved by hiring accomplished analytical chemists who can develop and validate robust analytical methods around AMS. We are now turning the company’s full-time resources to scaling-up that service. Graham will help us customize our approach to novel cost-efficient clinical investigations and to continue applying our analytical expertise in new areas of drug research and non-pharmaceutical product development”

 

Xceleron and Molecular Profiles Announce Biopharmaceutics Partnership

October 30, 2014

We are pleased to announce a new partnership between Xceleron and biopharmaceutics technology leader Molecular Profiles.

The alliance aims to simplify biopharmaceutics decisions using technology and efficient design of clinical investigations.  Molecular Profiles has developed a unique Molecular Profiles Roadmap to investigate, evaluate and recommend a formulation development pathway that is the best option based on science.  Xceleron has developed a scientifically superior approach to determining clinical drug disposition using LC + AMS.  Together we can satisfy a real market need for science and technology to efficiently help with clinical biopharmaceutics decisions.

We look forward to a very active relationship with Molecular Profiles along the lines of that established with JCL.

 

 

GSK publish on the use of AMS to determine the absolute bioavailability of dabrafenib, a BRAF inhibitor, in patients

November 28, 2013

In a recent publication in the Journal of Clinical Pharmacology, GSK have published data on the use of [14C] labelled IV microtracer for the determination of absolute bioavailability of dabrafenib in oncology patients. This is the first time that the use of this approach in patients has been published, and it demonstrates the value of the technique for gaining a greater understanding of the fundamental pharmacokinetics. Furthermore, by using this approach GSK were able to shorten the study time frame and it allowed for simultaneous collection of IV and oral pharmacokinetic parameters, thus reducing variability.

Particularly where patients as clinical research participants are concerned, IV microtracer studies offer an innovative and efficient approach for assessing absolute bioavailability and may be applied across a range of therapeutic areas and compound classes.

For further information on this paper and a copy of the abstract, please follow this link

For more information on how this approach can be used in drug development, please do not hesitate to contact Xceleron by email:
info@xceleron.com

 

Xceleron to Present Two Posters at Forthcoming AAPS Annual Meeting in San Antonio

October 21, 2013

Xceleron is pleased to announce that they will be presenting 2 posters in collaboration with Incyte Corp and Neurocrine Biosciences Inc at the forthcoming AAPS Annual Meeting and Exposition to be held in Henry B. Gonzalez Convention Center, San Antonio, from 10th – 14th November 2013.

The Incyte poster (Application of Accelerator Mass Spectrometry in Early Clinical Development; #R6343) describes the use of Accelerator Mass Spectrometry (AMS) for the timely identification of 2 human metabolites that would have been neglected if simple qualitaTIVE LC/MS peak analysis had been used, thus allowing early identification of major metabolites and an early assessment of safety margins in accordance with FDA MIST and ICH M3 regulatory guidance. This poster will be presented between 08:30-11:30 on Thu 14 Nov.

The Neurocrine poster (Confirmation of the Selectivity of an LC+AMS Assay by Cross-Validation with LC MS/MS; Poster #M1360) describes a novel approach to validating the selectivity of LC+AMS by cross validation with a selective LC-MS/MS assay.

Copies of these posters can now be downloaded from our Resources page by clicking on this link.

 

Confirmation of the Selectivity of an LC+AMS Assay by Cross-Validation with LC-MS/MS

July 23, 2013

Published: 14th Annual Land O’Lakes Bioanalytical Conference, 15-18 July 2013
Authors: Connell Cunningham*, Marie Croft*, Anthony R Hall*, David M Higton*, Mark A Seymour*, Rosa Luo†, Evan Smith†, and Ajay Madan†
*: Xceleron Inc, Germantown, MD; †: Neurocrine Biosciences Inc, San Diego, CA

Objectives: Liquid chromatography with Accelerator Mass Spectrometry detection (LC+AMS) is increasingly used as a bioanalytical technique. It is not susceptible to matrix effects and is independent of chemical structure, because the sample graphitization procedure converts all 14C-containing material in samples into a common analyte, solid carbon. It is, therefore, essential that the analyte is chromatographically resolved from any other 14C-containing species. Although the accuracy and precision of a LC+AMS assay is comparable to liquid chromatography with tandem mass spectrometry (LC-MS/MS), the approach to validation of selectivity does differ. This poster describes a novel approach involving cross-validation with a LC MS/MS method.

Methods: Selected plasma samples from a clinical study whereby healthy human subjects received a single oral dose of [14C]-NBI-X were analyzed by LC+AMS. Aliquots of the same samples were independently analysed using a validated LC MS/MS assay, and results obtained from the two orthogonal methods compared.

Results: Selected samples collected from different subjects after dosing were analysed by both methods. The difference between the results was within ± 15% of the mean for all samples, and there was no apparent temporal trend in the data.

Implications: The differences between the concentrations measured by LC+AMS and LC MS/MS in the same sample were well within the known precision of each assay. Thus, it was concluded that the fraction isolated contained no 14C-labelled species other than [14C]-NBI-X and that the LC+AMS assay was highly selective. This methodology is a valuable tool to unambiguously verify the selectivity of LC+AMS assays during method validation.

Download Document »

 

  • Latest News

    Xceleron latest presentation

    Read more »

  • What our clients are saying about us...

    "...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."

    See more client quotes »

  • Get Phase II Ready

    Find out how we can help you accelerate your drug-development program.

    Email us now »

© Xceleron 2013 All Rights Reserved.